Members |
targetComponentId |
Mental disorders NOS |
Mental disorder |
mental retardering |
Intellectual disability |
mental retardering, speciale |
Intellectual disability specialty |
Mental handicap (specialty) |
Intellectual disability specialty |
Mental handicap (specialty) |
Intellectual disability specialty |
Mental handicap psychiatry department |
Intellectual disability psychiatry department (environment) |
psykiatrisk afdeling for mental retardering |
Intellectual disability psychiatry service |
årlig psykiatrisk undersøgelse udført |
Annual physical examination for people with mental illness completed |
psykiatrisk kriseplan |
Mental health crisis plan |
personlig psykiatrisk helbredsplan |
Mental health personal health plan |
mental retardering |
Intellectual disability |
Mental retardation NOS |
Intellectual disability |
Mental retardation NOS |
Intellectual disability |
Mental retardering, ikke nærmere specificeret |
Intellectual disability |
Screening for mental retardering |
Intellectual disability screening |
Screening for mentalt/udviklingsmæssigt handicap |
Screening for developmental disorder (procedure) |
Screening for mentalt/udviklingsmæssigt handicap, ikke nærmere specificeret |
Screening for developmental disorder (procedure) |
Mental/developmental handicap screening NOS |
Screening for developmental disorder (procedure) |
menthol 35,55 mg inhalationspulver kapsel |
Product containing only menthol in pulmonary dose form (medicinal product form) |
Mepacrine hydrochloride 100mg tablet |
Mepacrine hydrochloride 100 mg oral tablet |
pethidinhydrochlorid 100 mg/ml injektionsvæske, opløsning, ampul |
Product containing only pethidine in parenteral dose form (medicinal product form) |
pethidinhydrochlorid 50 mg/5 ml syrup |
Pethidine hydrochloride 10 mg/mL oral solution |
pethidinhydrochlorid 50 mg/ml injektionsvæske, opløsning, ampul |
Product containing only pethidine in parenteral dose form (medicinal product form) |
pethidinhydrochlorid 50 mg + promethazinhydrochlorid 50 mg injektionsvæske, opløsning, hætteglas |
Product containing only pethidine and promethazine (medicinal product) |
mepivacainhydrochlorid 3 %/levonordefrin 1:20.000 injektionsvæske, opløsning, hætteglas |
Corbadrine 50 microgram/mL and mepivacaine hydrochloride 30 mg/mL solution for injection |
mepivacainhydrochlorid 30 mg + natriumklorid 3 mg injektionsvæske, opløsning, hætteglas |
Mepivacaine only product |
mepivacainhydrochlorid + adrenalin 2 %/1:100.000 cylinderampul |
Adrenaline 10 microgram/mL and mepivacaine hydrochloride 20 mg/mL solution for injection |
Mepivacaine hydrochloride+epinephrine 2%/1:100,000 cartridge |
Adrenaline 10 microgram/mL and mepivacaine hydrochloride 20 mg/mL solution for injection |
Meptazinol 100mg/1mL injection |
Product containing precisely meptazinol (as meptazinol hydrochloride) 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
meptazinol 100 mg/ml injektionsvæske, opløsning, ampul a 1 ml |
Product containing precisely meptazinol (as meptazinol hydrochloride) 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Meptazinol 200mg tablet |
Meptazinol (as meptazinol hydrochloride) 200 mg oral tablet |
mercurophyllininjektion |
Mercurophylline |
merselen-patch |
Polyester mesh (physical object) |
Mesalamine 250mg capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
mesalazin kapsel med modificeret udløsning a 250 mg |
Product containing only mesalazine in oral dose form (medicinal product form) |
Mesalamine 250mg prolonged-release oral capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
Mesalamine 375mg m/r capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
Mesalamine 375mg prolonged-release oral capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
mesalazin 1 g/100 ml retentionsklysma |
Mesalazine only product in rectal dose form |
Mesalazine 1g/100mL retention enema |
Mesalazine only product in rectal dose form |
mesalazin 2 g/59 ml klysma |
Mesalazine only product in rectal dose form |
Mesalazine 500mg/sachet gastro-resistant and prolonged-release oral granules |
Product containing only mesalazine in oral dose form (medicinal product form) |
mesalazin 500 mg brev granulat med modificeret udløsning |
Product containing only mesalazine in oral dose form (medicinal product form) |
Mesalazine duplicate deleted |
Product containing mesalazine (medicinal product) |
Mesenteric venous thrombosis |
Thrombosis of mesenteric vein |
Mesio-occlusion |
Mesio-occlusion of teeth |
mesonefrisk tumor |
Wolffian tumor of uncertain behavior (morphologic abnormality) |
mesoridazinbesylat 10 mg/ml injektionsvæske, opløsning, ampul |
Product containing precisely mesoridazine 10 milligram/1 milliliter conventional release solution for injection (clinical drug) |
mesoridazinbesylat 25 mg/ml injektionsvæske, opløsning, ampul |
Product containing precisely mesoridazine 25 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Mesothelioma, biphasic, benign |
Mesothelioma, benign |
metabolisk acidose forårsaget af indtagelse af medikamenter OG/ELLER kemiske stoffer |
Metabolic acidosis |
Metabolic disease, NEC |
Metabolic disease |
Metabolic function test NOS |
Metabolic function test |
Metabolic function test NOS |
Metabolic function test |
Metabolic marker |
Inborn errors of metabolism marker |
Metabolic monitoring NOS |
Metabolic monitoring procedure |
Metabolic monitoring NOS |
Metabolic monitoring procedure |
Metacarpal X-ray |
Plain X-ray of metacarpal bone |
Metacarpal X-ray |
Plain X-ray of metacarpal bone |
Røntgenundersøgelse af metakarpalknogle |
Plain X-ray of metacarpal bone |
Metaiodobenzylguanidine[123I] 74MBq/mL injection |
Iobenguane (131-I)-containing product in parenteral dose form |
metaiodobenzylguanidin[123I] 74 MBq/ml pulver til injektionsvæske, opløsning, hætteglas |
Iobenguane (131-I)-containing product in parenteral dose form |
Metaiodobenzylguanidine[131I] 37MBq/mL injection |
Iobenguane (131-I)-containing product in parenteral dose form |
metaiodobenzylguanidin[131I] 37 MBq/ml pulver til injektionsvæske, opløsning, hætteglas |
Iobenguane (131-I)-containing product in parenteral dose form |
metaiodobenzylguanidin[131I] 370 MBq/ml injektionsvæske |
Iobenguane (131-I)-containing product in parenteral dose form |
metaiodobenzylguanidin[131I] 37 MBq/ml diagnostisk injektionsvæske |
Iobenguane (131-I)-containing product in parenteral dose form |
metaiodobenzylguanidin[131I] 9,25 MBq/ml diagnostisk injektionsvæske |
Iobenguane (131-I)-containing product in parenteral dose form |
Metal engineering machiner NOS |
Engineering machiner |
Metal engineering machiner NOS |
Engineering machiner |
Metal processor/treater NOS |
Metal processer (occupation) |
Metal processor/treater NOS |
Metal processer (occupation) |
Metal production fitter NOS |
Metal production fitter |
Metal production fitter NOS |
Metal production fitter |
Metal/electrical worker NOS |
Metal/electrical worker |
Metal/electrical worker NOS |
Metal/electrical worker |
Metallocarboxypeptidase |
Metallocarboxypeptidase |
Metalloproteinase |
Metalloproteinase |
metaproterenol tablet a 20 mg |
Orciprenaline sulfate 20 mg oral tablet |
metaproterenolsulfat 0,65 mg inhalationsaerosol |
Orciprenaline only product in pulmonary dose form |
metaproterenolsulfat 15 mg/ml aerosol |
Product containing precisely orciprenaline sulfate 15 milligram/1 milliliter conventional release solution for inhalation (clinical drug) |
metastasering stadium M1a |
American Joint Committee on Cancer cM1a (qualifier value) |
metastasering stadium M1b |
American Joint Committee on Cancer cM1b (qualifier value) |
metastasering stadium M1c |
American Joint Committee on Cancer cM1c (qualifier value) |
metastasering stadium M2 |
American Joint Committee on Cancer cM1 (qualifier value) |
metastasering stadium M3 |
American Joint Committee on Cancer cM1 (qualifier value) |
metastasering stadium M4 |
American Joint Committee on Cancer cM1 (qualifier value) |
metastasering stadium pM1 |
American Joint Committee on Cancer pM1 (qualifier value) |
Metastasizing pleomorphic adenoma |
Pleomorphic adenoma |
Metastatic apocrine adenocarcinoma to skin |
Metastatic apocrine adenocarcinoma (disorder) |
Metastatic carcinoid tumor |
Metastatic well-differentiated neuroendocrine tumor (disorder) |
Metastatic carcinoid tumor |
Metastatic well-differentiated neuroendocrine tumor (morphologic abnormality) |
Metastatic carcinoma to female breast |
Metastatic carcinoma to breast |
Metastatic carcinoma to male breast |
Metastatic carcinoma to breast |
Metastatic cholangiocarcinoma to biliary tract |
Metastatic cholangiocarcinoma (morphologic abnormality) |
Metastatic cholangiocarcinoma to perihilar bile duct |
Metastatic cholangiocarcinoma |
Metastatic collecting duct carcinoma to kidney |
Metastatic collecting duct renal cell carcinoma (disorder) |
Metastatic cystic renal cell carcinoma to kidney |
Metastatic cystic renal cell carcinoma |
Metastatic eccrine porocarcinoma to skin |
Metastatic eccrine porocarcinoma |
Metastatic infiltrating duct carcinoma to female breast |
Metastatic infiltrating duct carcinoma to breast (disorder) |
Metastatic lobular carcinoma to breast |
Metastatic lobular carcinoma (disorder) |
Metastatic lobular carcinoma to left female breast |
Metastatic lobular carcinoma (disorder) |